Aduhelm (aducanumab) - Alzheimer's Drug - First Choice Neurology - Jeffrey Gelblum, MD

Neurologist, Jeffrey Gelblum, MD of First Choice Neurology talks about the new Alzheimer's drug approved by the FDA on Monday, June 7, 2021. Biogen's aducanumab is the first-ever drug to slow the progression of Alzheimer’s disease and treat mild cognitive decline. Alzheimer's Disease is a type of dementia-causing problems with memory loss and other cognitive abilities. Symptoms usually develop slowly and worsen over time. In the early stages, memory loss is mild, but with late-stage Alzheimer's, individuals lose the ability to carry on a conversation. Alzheimer's disease is progressive, where dementia symptoms gradually worsen over a number of years. For more information about aducanumab and Alzheimer's disease, visit https://www.fcneurology.net/ #aducanumab #alzheimersdrug #firstchoicenuerology